Co-diagnostics vs Insight Molecular Diagnostics
Insight Molecular Diagnostics is the larger business, with $4.1m of revenue in fiscal 2025 against $622,489 for Co-diagnostics (6.5 times as much). Insight Molecular Diagnostics grew faster (115.6% against -84.1%). Insight Molecular Diagnostics kept more of each dollar of sales as profit: a net margin of -1238.5% against -7533.6%.
| Latest fiscal year | Co-diagnosticsCODX, 2025 | Insight Molecular DiagnosticsIMDX, 2025 |
|---|---|---|
| Revenue | $622,489 | $4.1m |
| Revenue growth | -84.1% | 115.6% |
| Net income | −$46.9m | −$50.2m |
| Operating margin | -8058.8% | — |
| Net margin | -7533.6% | -1238.5% |
| Return on equity | -125.9% | — |
| Free cash flow | −$29.8m | −$25.4m |
| Cash | $11.9m | $11.6m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 115 | — |
| Market value | $1.7m | $90.7m |
| Price vs our value range | — | — |
| Moat score | 24 (Weak) | 20 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 14 buys, 0 sales |